% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Vogelgsang:140732,
      author       = {Vogelgsang, Jonathan and Vukovich, Ruth and Wedekind, Dirk
                      and Wiltfang, Jens},
      title        = {{H}igher {L}evel of {M}ismatch in {APOE}ε4 {C}arriers for
                      {A}myloid-{B}eta {P}eptide {A}lzheimer's {D}isease
                      {B}iomarkers in {C}erebrospinal {F}luid.},
      journal      = {ASN NEURO},
      volume       = {11},
      issn         = {1759-0914},
      address      = {London},
      publisher    = {Sage Publishing},
      reportid     = {DZNE-2020-07054},
      pages        = {175909141984552},
      year         = {2019},
      abstract     = {Cerebrospinal fluid (CSF) biomarkers are widely used in the
                      diagnosis of dementia. Even though there is a causal
                      correlation between apolipoprotein E ( APOE) genotype and
                      amyloid-beta (Aβ), the determination of APOE is currently
                      not supported by national or international guidelines. We
                      compared parallel measured CSF biomarkers of two independent
                      laboratories from 126 patients who underwent clinical
                      dementia diagnostics regarding the APOE genotype. APOE ε4
                      reduces Aβ1-42 (Aβ42) and Aβ42 to Aβ 1-40 ratio
                      (Aβ42/40) but not total Tau or phospho-181 Tau CSF levels.
                      Higher discordance rates were observed for Aβ42 and
                      subsequently for Aβ42/40 in APOE ε4 carriers compared with
                      noncarriers, and the correlation between the two
                      laboratories was significantly lower for Aβ42 in APOE ε4
                      positive patients compared with patients without APOE ε4.
                      These observations demonstrate that the evaluation of CSF
                      Aβ biomarkers needs to be interpreted carefully in the
                      clinical context. Different immunoassays, disparate cutoff
                      values, and APOE should be respected.},
      keywords     = {Aged / Aged, 80 and over / Alzheimer Disease: cerebrospinal
                      fluid / Alzheimer Disease: genetics / Amyloid beta-Protein
                      Precursor: cerebrospinal fluid / Apolipoproteins E: genetics
                      / Biomarkers: cerebrospinal fluid / Female / Genotype /
                      Heterozygote / Humans / Male / Middle Aged},
      cin          = {AG Wiltfang},
      ddc          = {610},
      cid          = {I:(DE-2719)1410006},
      pnm          = {342 - Disease Mechanisms and Model Systems (POF3-342)},
      pid          = {G:(DE-HGF)POF3-342},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31104469},
      pmc          = {pmc:PMC6535906},
      doi          = {10.1177/1759091419845524},
      url          = {https://pub.dzne.de/record/140732},
}